S. 2658 · 119th Congress · Health
Medication Affordability and Patent Integrity Act
Modifies patent and pricing rules for medications. AI-read
- IntroducedAug 1, 2025 Done
- CommitteeReported Jul 28, 2026 Done
- Senate floorAwaiting vote Current stage
- House floorNot yet Not reached yet
- Chambers agreeNot yet Not reached yet
- PresidentNot yet Not reached yet
What it does
This bill requires applicants seeking approval of a drug or licensure of a biological product to submit certain information about relevant patents to both the Food and Drug Administration (FDA) and the U.S. Patent and Trademark Office (USPTO).
Specifically, the bill requires applicants to make certifications and disclosures related to each applicable patent on a proposed drug or biological product. An applicable patent is a patent or patent application held or sought by the applicant for the drug or biological product (including a formulation or composition, method of use, or method of manufacturing).
For each applicable patent, an applicant must submit to the USPTO any information material to patentability that the applicant submitted to the FDA and any information provided by the FDA in response. The applicant must certify that this submission is complete and consistent with the information the applicant provided to the FDA.
Further, for each applicable patent, an applicant must certify that certain information submitted to the FDA is consistent with information the applicant provided to the USPTO. This is specific to statements or characterizations that are material to patentability and related to (1) an applicable patent (including a statement or characterization of relevant publicly known information), or (2) analytical data included in a new drug or biological product application.
The bill establishes a defense to a patent infringement action if the owner of an applicable patent negligently or intentionally failed to make the disclosures required by these provisions.
Congressional Research Service · summary of “Reported to Senate” version · Jul 28, 2026
Who lobbies on it
17 organizations, more than 98% of Senate bills · 51 filings · Q3 2025–Q3 2026One square per quarter since introduction, oldest left. Filled = named it that quarter.
-
Pharmaceutical Research and Manufacturers of America
5 of 5 quarters
“Issues related to competition pracitces in the pharmaceutical marketplace. S.1040 - Drug Competition Enhancement Act. S.1041 - Affordable Prescriptions for Patients Act. S.2658 - Medication Affordability and Patent Integrity Act (MAPIA). S.1095 - Stop STALLING Act. S.43 - Skinny Labels, Big Savings Act.”
$26.6M lobbying spend in 2026 to date, all issuesQ3 2026 filing
-
Biotechnology Innovation Organization
5 of 5 quarters
“…S.2658: Medication Affordability and Patient Integrity Act ---S.3014: Ensuring Timely Access to Generics Act ---Department of Commerce Patent Valuation Fee Proposal ---PTAB Reform ---PTO Proposed Rules on Terminal Disclaimer Practice ---Restrictions on Intellectual Property Rights ---Section 101 Modernization Foreign…”
$6.5M lobbying spend in 2026 to date, all issuesQ3 2026 filing
-
Viatris Inc
5 of 5 quarters
“S. 891, the Bipartisan Health Care Act Part D Formulary Design and Generic Drug Tiering HR 4132 / S.2027 - Prescription Information Modernization Act Medicaid Generics Penalty Implementation of the Inflation Reduction Act Drug Shortages S. 2658, The Medication Affordability and Patent Integrity Act”
$1.3M lobbying spend in 2026 to date, all issuesQ3 2026 filing
14 more organizations, every filingPROUpgrade
Organizations that named S. 2658 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. “Gave to” means the organization’s PAC gave to the member’s campaign in the 2025–26 cycle, net of refunds; it doesn’t mean the money was about this bill. Organizations may lobby for, against, or to change a bill; filings don’t say which. Source: Senate lobbying disclosures (LD-2) from lda.gov; PAC gifts from FEC filings; quotes are word for word from the “specific lobbying issues” field; where a filing lists many bills, the quote starts where it names this one.
Actions
6 actions · newest first- Jul 28, 2026Placed on Senate Legislative Calendar under General Orders. Calendar No. 528.
- Jul 28, 2026Committee on Health, Education, Labor, and Pensions. Reported by Senator Cassidy with an amendment in the nature of a substitute. Without written report.
- Jun 17, 2026Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.
- Mar 19, 2026Committee on Health, Education, Labor, and Pensions. Hearings held.
Show all 6 actionsShow fewer
- Aug 1, 2025Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- Aug 1, 2025Introduced in Senate